NASDAQ:SNY 15 December 2025

Pfizer (NYSE:PFE) Faces New Patent Claim After $96 Billion in COVID Vaccine Revenue

Pfizer Inc. shares rose 2.35% to $24.82 on Wednesday after Sanofi SA brought a new patent case over the Comirnaty COVID-19 vaccine. The gain suggests investors viewed the complaint as a possible charge against past vaccine earnings, rather than an immediate block on sales.

15 July 2026

NASDAQ:SNY·NYSE:PFE·Pharmaceuticals

Sanofi Stock (SAN.PA, SNY) Slides After Tolebrutinib Double Setback: FDA Delay, Trial Miss, and Fresh Analyst Forecasts (Dec. 15, 2025)

Sanofi stock is under pressure on December 15, 2025, after the French drugmaker disclosed two setbacks tied to its experimental multiple sclerosis medicine tolebrutinib—a regulatory delay in the U.S. for one progressive MS form and a failed Phase 3 endpoint in another. The update pushed Sanofi shares down about 4% in Paris trading, as investors recalibrated expectations for one of the company’s closely watched late-stage pipeline assets. Reuters+1

15 December 2025

EPA:SAN.PA·NASDAQ:SNY·Pharmaceuticals·Stock Market

NASDAQ:SNY 15 December 2025 - 15 July 2026

Pfizer (NYSE:PFE) Faces New Patent Claim After $96 Billion in COVID Vaccine Revenue

Sanofi Stock (SAN.PA, SNY) Slides After Tolebrutinib Double Setback: FDA Delay, Trial Miss, and Fresh Analyst Forecasts (Dec. 15, 2025)